Medical device specialist Bioteque reported a record-breaking 2025, with annual revenue reaching NT$2.135 billion (+3% YoY) and an EPS of $7.78. The fourth quarter alone set a new historical single-quarter high with an EPS of $2.24.

• High-Margin Drivers: The company’s TPU internal catheters, boasting a 70% gross margin, remain the primary growth engine. The newly inaugurated Yilan facility has doubled TPU capacity and will serve as the hub for high-margin product manufacturing.
• Future Capacity: Production for "soft bags" is currently at full capacity. To address global shortages, the board has approved the purchase of three large-scale machines for the Yilan plant, expected to be operational by the end of 2026. This is projected to drive a significant revenue "jump" in 2027.
• Dividend: The board proposed a cash dividend of NT$5.5, representing a 4.6% yield.

Resource: 邦特去年Q4、全年營運攻頂，EPS分別達2.24元、7.78元